Addition of pentoxifylline could reduce the side effects of fumaric acid esters in the treatment of psoriasis.
Friedrich
M
M
Sterry
W
W
Klein
A
A
Rückert
R
R
Döcke
W D
WD
Asadullah
K
K
D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003967:Diarrhea / Q000139:chemically induced / Q000517:prevention & control; D000069462:Dimethyl Fumarate; D005260:Female; D005483:Flushing / Q000139:chemically induced / Q000517:prevention & control; D005650:Fumarates / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010431:Pentoxifylline / Q000008:administration & dosage*; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy* / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism
D003879:Dermatologic Agents; D005650:Fumarates; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069462:Dimethyl Fumarate; D010431:Pentoxifylline